First Horizon Advisors, Inc. Exelixis, Inc. Transaction History
First Horizon Advisors, Inc.
- $3.53 Billion
- Q1 2025
A detailed history of First Horizon Advisors, Inc. transactions in Exelixis, Inc. stock. As of the latest transaction made, First Horizon Advisors, Inc. holds 350 shares of EXEL stock, worth $14,882. This represents 0.0% of its overall portfolio holdings.
Number of Shares
350
Previous 339
3.24%
Holding current value
$14,882
Previous $11,000
9.09%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding EXEL
# of Institutions
613Shares Held
257MCall Options Held
1.57MPut Options Held
730K-
Black Rock Inc. New York, NY33.5MShares$1.42 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA28.7MShares$1.22 Billion0.02% of portfolio
-
Farallon Capital Management LLC San Francisco, CA22.5MShares$958 Million4.78% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny14.8MShares$630 Million0.88% of portfolio
-
State Street Corp Boston, MA11.8MShares$501 Million0.02% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $13.7B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...